MarketVIEW Travel Diseases  ·  2020 edition, updated April 2023

Zika Virus
Vaccines Forecast

Zika virus transmission has now been documented in 97 countries and territories worldwide, with new spread confirmed in the Seychelles, Burkina Faso and Kenya's Lamu Island since 2024. There is still no licensed vaccine, but Moderna's mRNA-1893 has become the field's furthest-advanced candidate yet, now in Phase II. This is a comprehensive, wide geography commercial assessment of the Zika vaccine opportunity, drawing on VacZine Analytics' long standing, independent authority in travel disease vaccine markets.

97 Countries With ZIKV Transmission mRNA-1893: Phase II, 809 Participants Endemic, Stockpile & Traveler Markets WHO High-Priority Pathogen (PHEIC Potential)
Product catalogue
VAMV068
2020 edition, updated April 2023

Format
PDF (~150 slides) + Excel model
Markets modelled
Endemic, stockpile & traveler
Scenarios
LO / BASE / HI pricing
Forecast horizon
To 2035
Approach
Value/volume demand model
Base edition
2020, updated April 2023
Availability
Syndicated / bespoke
97
Countries/territories with current
or previous ZIKV transmission
~200,000
Probable/confirmed Brazilian ZIKV
cases persisting since 2017
809
Participants in mRNA-1893's
ongoing Phase II trial
0
Licensed Zika vaccines
or treatments available today
Disease background

A quietly spreading flavivirus, still without a licensed vaccine

This review sets out the current disease background, global spread and R&D competitive landscape for Zika virus, a decade on from its declaration as a global public health emergency.

WHO May 2026 epidemiology update

Pathogen overview - Zika virus (ZIKV)

Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family, which also includes yellow fever virus, Japanese encephalitis virus and dengue virus. First identified in the 1940s, ZIKV was only recognised as a major cause of severe disease relatively recently. The WHO declared the 2015/16 Zika outbreak a Public Health Emergency of International Concern in February 2016. Most ZIKV infections are mild or asymptomatic, but the virus is an established cause of congenital Zika syndrome, including neonatal microcephaly, and of Guillain-Barre syndrome in adults. In Brazil, an estimated 200,000 probable and confirmed ZIKV cases have persisted since 2017 following the 2015/16 peak, with 3,707 confirmed neonatal microcephaly cases reported by the Ministerio de Saude, though many remain under investigation.

ZIKV's geographic footprint has continued to widen rather than recede. WHO's most recent epidemiology update confirms evidence of current or previous autochthonous ZIKV transmission in 97 countries and territories, up from 89 as of 2021. New geographic evidence since 2024 includes sporadic cases in Senegal, the first molecular confirmation of infection in Burkina Faso and on Kenya's Lamu Island, and newly documented autochthonous transmission in the Seychelles. Asia saw a notable 2024 outbreak in India, with 151 confirmed cases across Maharashtra, Karnataka and Gujarat, though no associated microcephaly or Guillain-Barre cases were reported. Autochthonous transmission, while rare, has also occurred in the US Gulf Coast and Florida, and in France's Var department in 2019, underscoring the risk to non-endemic regions wherever Aedes mosquitoes are established. WHO now designates Zika a high-priority pathogen with the potential to cause future public health emergencies, and notes that no vaccine or treatment is currently available.

Against that backdrop, the R&D field's most advanced candidate has reached its deepest clinical stage yet. Moderna's mRNA-1893, encoding the prM and E proteins of a Brazilian ZIKV strain, demonstrated durable immunogenicity beyond a year and a favourable safety profile in Phase I testing, and has since advanced into a Phase II trial (NCT04917861) enrolling 809 participants across the US and Puerto Rico. Valneva's second-generation candidate, VLA1601, entered a placebo-controlled Phase I trial of around 150 participants in the US, with topline data expected in the first half of 2025. Takeda's earlier TAK-426 candidate remains part of the field's history, though with a lower recent public profile than the two active late-stage programmes.

2026 97 countries/territories with ZIKV transmission  |  ~200,000 Brazil cases since 2017  |  mRNA-1893 in Phase II (809 participants)  |  VLA1601 Phase I data expected  |  still no licensed vaccine
Product & competitor landscape

The field's deepest clinical progress yet, a decade after the PHEIC

A decade on from the 2016 emergency declaration, two candidates now anchor a genuinely active late-stage Zika vaccine pipeline.

  • ModernaTXPhase II, ongoing
    mRNA-1893 mRNA, prM/E antigen
    The field's furthest-advanced candidate. Phase I data showed durable immunogenicity beyond a year and a favourable safety profile; a Phase II trial (NCT04917861) is now enrolling 809 participants across the US and Puerto Rico.
  • Valneva SEPhase I, data expected H1 2025
    VLA1601 Second-generation candidate
    A placebo-controlled Phase I trial enrolling around 150 participants aged 18 to 49 in the US, with topline data expected in the first half of 2025.
  • Takeda VaccinesEarlier-stage, lower recent profile
    TAK-426
    Part of the field's earlier development history alongside mRNA-1893 and VLA1601, though with less recent public disclosure than the two currently active late-stage programmes.
  • WHO / national surveillance bodiesActive surveillance
    Global ZIKV transmission monitoring
    Periodic WHO epidemiology updates and national vector surveillance continue to track ZIKV's expanding geographic footprint, now spanning 97 countries and territories.
Field inflection point
Phase II

Moderna's advance of mRNA-1893 into an 809-participant Phase II trial is the deepest clinical progress the Zika vaccine field has ever achieved, arriving just as ZIKV's confirmed geographic footprint has widened to 97 countries and territories. That combination, genuine late-stage momentum set against genuinely wider spread, reframes the commercial opportunity across endemic, stockpile and traveler market segments alike. The VacZine Analytics model quantifies this opportunity under LO/BASE/HI pricing scenarios reflecting differing degrees of pipeline success.

Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, current R&D status and scenario-based demand forecasting across endemic, stockpile and traveler markets to 2035.

Endemic, stockpile & traveler forecast

Value ($m) and volume (million doses) forecasts to 2035 across public and private endemic markets, stockpile procurement, and traveler segments.

Competitor & pipeline review

Full review of Moderna's mRNA-1893, Valneva's VLA1601 and the wider Zika vaccine R&D landscape.

TPP, launch timing & pricing

Target product profile, launch timeframe assumptions, pricing and market penetration estimates for all key commercial segments.

LO/BASE/HI scenario forecasts

Three pricing-justified revenue scenarios reflecting differing pipeline-progression and market-access assumptions.

Disease burden & epidemiology

Global spread data updated through WHO's May 2026 epidemiology update, spanning 97 countries and territories.

Non-endemic spread & travel risk

Assessment of autochthonous transmission risk in non-endemic regions, including the US Gulf Coast, Florida and southern Europe.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the market-segment and scenario framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.

Market segmentGeographySectorVaccine statusRevenue scenario
Endemic - women of childbearing ageAmericas, Africa, AsiaPublic/privatePre-licensureModelled
Stockpile / outbreak responsePAHO region & ROWPublicPre-licensureModelled
Travelers to endemic regionsGlobal source marketsPrivatePre-licensureModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll geographiesAll sectorsAll scenarios$███m
Full model in the licensed workbook
Endemic, stockpile & traveler markets · to 2035 · LO/BASE/HI scenarios
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the Zika vaccine opportunity across endemic, stockpile and traveler markets.

  • Executive presentation (~150 slides, PDF) - disease background, epidemiology, R&D status and full commercial assessment with supporting narrative and references
  • MS-Excel forecast model - value ($m) and volume (million doses) predictions to 2035 across all key commercial segments
  • LO/BASE/HI pricing scenarios - three forecast scenarios based on differing pricing justifications and pipeline outcomes
  • Competitor intelligence - Moderna's mRNA-1893, Valneva's VLA1601 and the wider Zika vaccine R&D landscape
  • Updated epidemiology module - WHO's May 2026 update confirming ZIKV transmission across 97 countries and territories
  • TPP, launch timing & penetration estimates - target product profile, launch timeframe and pricing/penetration assumptions for endemic, stockpile and traveler segments
Target audience

Built for organisations weighing the Zika vaccine opportunity

Most valuable to teams evaluating the Zika virus vaccine market against their own pipeline, BD ambitions or investment thesis, now that the field has reached its deepest clinical stage yet.

Vaccine developers

Positioning and commercial feasibility assessment for Zika candidates at any stage, informed by mRNA-1893's Phase II progress.

Corporate strategy & BD

Validate the size and structure of a market with no incumbent vaccine, now that the leading candidate has proven late-stage progress is achievable.

Investors & analysts

Independent assessment of pipeline risk and commercial upside for due diligence on Moderna, Valneva and future Zika entrants.

Public health & travel medicine bodies

Demand modelling and non-endemic spread risk review to support future Zika stockpile and traveler advisory planning.

Researchers & academia

Comprehensive epidemiology and R&D landscape for grant, translational and congenital Zika syndrome research planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions across endemic, stockpile and private traveler channels worldwide.

About this analysis · VAMV068

VacZine Analytics has tracked travel disease vaccine markets since our earliest editions, positioning us to reassess the Zika vaccine opportunity the moment the field's leading candidate reached Phase II. This is a genuinely comprehensive analysis with a wide geographic focus spanning endemic, stockpile and traveler markets, and it has been well received by clients across the field for the depth of its epidemiology and scenario modelling. Few groups have followed this market as closely, and that recognised, independent expertise underpins everything in the analysis.

This 2020 edition, updated April 2023, has been further refreshed to incorporate WHO's May 2026 epidemiology update confirming ZIKV transmission across 97 countries and territories, and the R&D field's advance to Moderna's 809-participant Phase II trial. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV068 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Zika virus analysis, a briefing call is included on request.